【摘 要】
：
Objectives: Stem cells provide potential treatment for Parkinson s disease (PD).Since human umbilical cord mesenchymal stem cells (hUC-MSCs) have been reported to have multipotent ability and low immu
【机 构】
：
Centre for Stem Cells and Regenerative Medicine, Liaocheng University/Liaocheng People's Hospital,L
【出 处】
：
第十一届全国再生医学(干细胞与组织工程)学术研讨会暨第七届全国组织工程与再生医学大会
论文部分内容阅读
Objectives: Stem cells provide potential treatment for Parkinson s disease (PD).Since human umbilical cord mesenchymal stem cells (hUC-MSCs) have been reported to have multipotent ability and low immunogenicity, we have transplanted the hUC-MSCs to 6-hydroxydopamine (6-OHDA)-induced rat model of PD to explore therapeutic effects of hUC-MSCs for Parkinson s disease (PD).Methods: The rat PD model was induced by injection of 6-OHDA in the substantia nigra of the middle brain.5X105 cells of hUC-MSCs were transplanted to the PD rats by injecting cells to the striatum at the same side as the lesion side of the middle brain and the neurological behavior tests of the PD rats was measured at 4, 8, 12, and 16 weeks after transplantation.Immunostaining was used to analyze the cell migration and neural differentiation of hUC-MSCs in vivo.Results:After measurement of the locomotive behaviors of the 6-OHDA-induced PD rats, the confirmed PD rats were randomly grouped into 2 groups: Group of hUC-MSC transplantation and group of sham-control.We found that transplanted hUC-MSCs significantly improved the locomotive activities and have neuroprotective effects in rat PD models.hUC-MSC cells were found to survive and integrate into the brain of transplanted PD rats and differentiated into neurons and dopamine neurons in vivo.The potential molecular mechanism of hUC-MSC transplantation in improving motor deficits of PD rats is mediated by cell replacement,secretion of neurotrophic factors and release of immune-cytokines through transplanted hUC-MSCs.Conclusion: hUC-MSC has potentials to be used as stem cell source for the transplantation therapy of PD as these cells have neuroprotective role to improve the movement deficits of the 6-OHDA rat model.
其他文献
丹鳖胶囊是由广州白云山潘高寿药业股份有限公司生产的国家新药中药,其药物组成为当归、丹参、三七、三棱、莪术、鳖甲、海藻、桃仁、桂枝、白术、杜仲、半枝莲,共12味中药,具有抗癌消肿瘤、活血化瘀、软坚散结之功效,临床适应症为气滞血瘀所致子宫肌瘤、盆腔炎性包块症见小腹胀痛、腰骶酸痛、带下量多、肛门坠胀、舌暗有斑.丹鳖胶囊组方合理,疗效显著,2010年度荣获中华中医药学会科学技术二等奖.现医者不断挖掘与探索
目的：观察丹鳖胶囊治疗单纯性卵巢囊肿的临床疗效.方法：选取单纯性卵巢囊肿102例,给予口服丹鳖胶囊治疗,观察临床症状改善及超声检查包块缩小情况.3个月为一疗程,并随访半年,观察临床症状改善及超声检查包块缩小情况.结果：有效率为86.3％,其中包块最大直径5cm以下与5cm以上者疗效对比,结果：卵巢囊肿直径5-7cm组23例,治愈0例,显效4例,有效14例,无效5例,总有效率为78.3％;卵巢囊肿大
中成药丹鳖胶囊具有活血化瘀,软坚散结,消肿止痛,止血抗肿瘤的作用,本文介绍妇科临床辨证属血瘀证之疾病,运用丹鳖胶囊治疗均取得较好效果,值得临床推广应用.
慢性盆腔炎即盆腔炎性疾病后遗症,指女性内生殖器官包括子宫、输卵管、卵巢及其周围的结缔组织、盆腔腹膜等处发生感染时的炎症的总称.主要是因为急性盆腔炎治疗不及时或不彻底而形成子宫体炎、输卵管炎、卵巢炎、盆腔结缔组织炎等.慢性盆腔炎经久不愈而反复发作,具有病程长、病情缠绵、复发率高等特点.临床表现以反复下腹疼痛、腰骶酸痛、白带增多为主,多伴有月经失调、异位妊娠、输卵管阻塞不孕.笔者临床应用丹鳖胶囊治疗慢
目的：对比丹鳖胶囊为主的周期性中成药联合方案与小剂量米非司酮给药方案治疗子宫内膜异位症的临床疗效.方法：子宫内膜异位症患者随机分为试验组和对照组,每组各42例,试验组给予丹鳖胶囊为主的中成药周期联合方案,对照组给予小剂量米非司酮口服,连续治疗3个月,观察治疗前后症状、体征,B超观测盆腔包块,外周血血清CA-125浓度.结果：两组治疗后,均能有效改善临床症状和体征,缩小盆腔包块,降低血清CA-125
丹鳖胶囊是广州白云山潘高寿药业股份有限公司生产的国家级新药中药,其药物组成为当归、丹参、三七、三棱、莪术、鳖甲、海藻、桃仁、桂枝、白术、杜仲、半枝莲,具有抗癌消肿瘤,活血化瘀、软坚散结之功效,对丹鳖胶囊药物配伍特点加以分析,挖掘与探索其治疗机制,临床用于气滞血瘀所致子宫肌瘤、盆腔炎性包块等妇科疾病,丹鳖胶囊以其疗效显著,一直作为妇科临床治疗子宫肌瘤、盆腔炎性包块等疾的首推中成药物.
目的：探讨丹鳖胶囊抗炎作用效果观察.方法：采用随机对照重复的方法,用化学药、中药对照,用肉芽肿法、足跖浮肿法、铁板法和扭体法,从细胞因子(分子)和细胞两个水平客观地观察了丹鳖胶囊抗炎、镇痛效果.结果：丹鳖胶囊高剂量组,SOD活性有明显的上升(P＜0.01),MDA、PEG2、TNF值均有明显的下降(P＜0.05),可显著减轻肉芽肿的干湿重量和角叉菜胶致大鼠踝关节肿胀(P＜0.01),显著减少醋酸致
目的：研究和探讨丹鳖胶囊结合中药灌肠配合输卵管介入术治疗输卵管阻塞性不孕症的疗效.方法：90例输卵管阻塞性不孕症患者随机分为两组,两组均于月经干净后3～7天内行输卵管介入术,并于下个月经周期常规行宫腔输卵管通液术1次,注入香丹注射液40ml,治疗组(n=50)于月经周期第5天开始加服丹鳖胶囊,每次5粒,每天3次口服,每月连服20天;于月经周期第7天开始中药灌肠,每天1次,每月连用14天.3个月为1
目的：观察丹鳖胶囊治疗子宫肌瘤的疗效,减少子宫肌瘤手术率.方法：2007年1月～2010年1月应用丹鳖胶囊治疗子宫肌瘤50例,并与桂枝茯苓胶囊治疗子宫肌瘤50例作对照治疗.结果：治疗组50例中,痊愈6例,显效27例,有效13例,无效4例,总有效率92％.对照组50例,痊愈2例,显效21例,有效10例,无效17例,总有效率66％.两组总有效率比较有统计学意义(P＜0.01).结论：丹鳖胶囊治疗子宫肌
目的 本研究通过基因芯片筛选DV病人和健康人的miRNAs表达谱差异,进一步研究microRNA调控EPCs的机制和探讨其能否作为治疗DVT的潜在靶点。方法 通过基因芯片筛选DVT病人和健康人的miRNAs表达谱差异,qRT-PCR验证miR-483-3p在病人中的表达量；体外实验通过上调和下调miR-483-3p观察其对EPCs的迁移、成血管、凋亡的影响,通过生物信息学、荧光素酶报告实验预测mi